The Center for Biosimilars® recaps the top news for the week of February 11, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 11.
Number 5: Samsung Bioepis has announced a new licensing agreement with the private equity firm C-Bridge Capital that will allow the drug maker to expand its reach into China.
Number 4: A recent Australian study found that infliximab reduces short-term costs versus colectomy in patients with acute severe ulcerative colitis, and biosimilars could drive costs down even more.
Number 3: A recent study examining Medicare Part D reimbursement policies for off-label uses found that coverage decisions could hamper patient access.
Number 2: In a long-running patent dispute, AbbVie has been ordered to produce documents related to its efforts to obtain patents to shield Humira from biosimilar competition.
Number 1: During a presentation at the Access! 2019 meeting, an IQVIA executive broke down market share data for US biosimilars.
Finally, last week, our e-newsletter asked whether you think that all biosimilars, not just interchangeable ones, should be substitutable at the pharmacy level.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.